Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study.
Sohee ParkHan Eol JeongIn Sun OhSung Woo ParkSung Hoon YuChang Beom LeeJu Young ShinPublished in: BMJ open (2024)
These findings suggest that dual or triple therapies of evogliptin for the management of type 2 diabetes in routine clinical practice present no cardiovascular harms, but could alternatively offer cardiovascular benefits in this patient population.